Venus Remedies Limited is a distinguished entity within the pharmaceutical sector, acclaimed for its leading role in the production of meropenem antibiotics and its expanding knowledge of drugs addressing antimicrobial resistance (AMR).
On December 9, 2024, Venus Remedies share price reached an intraday peak of ₹355 per share, climbing 6% during trading on the BSE. This increase followed the company’s announcement on Friday regarding its acquisition of marketing authorisation for Pemetrexed 500 mg—a chemotherapeutic medication widely utilised for treating lung cancer and mesothelioma—in the Philippines.
The company stated in an exchange filing, “This authorisation represents a pivotal achievement in our quest to enhance our footprint within the rapidly expanding pharmaceutical market of Southeast Asia.”
In terms of the company’s financial performance, revenue experienced a slight decline, falling from ₹167.72 crore in Q2FY24 to ₹167.45 crore in Q2FY25. Concurrently, net profit significantly decreased by 68%, dropping from ₹9.94 crore to ₹3.51 crore.
Analysis of the company’s key ratios reveals an improvement in return on equity, which rose from 5.77% in FY22-23 to 5.84% in FY23-24, while return on capital employed increased from 7.37% to 8.17%. The net profit margin (NPM) for the fiscal year 23-24 stands at 4.73%.
Venus Remedies Expansion Plan
Venus Remedies is set on enhancing its presence within governmental institutions throughout India, taking advantage of the rising demand for antimicrobial products. Furthermore, the company intends to broaden its global footprint, aiming to establish a presence in 100 countries by 2025.
The company is committed to creating innovative therapies aimed at combating Antimicrobial Resistance (AMR) due to its considerable implications for global health. Additionally, it plans to venture into the consumer healthcare sector, with plans to introduce pioneering products in pain management, gastroenterology, and vitamins over the next five years.
As of 2:02 pm, Venus Remedies Ltd. shares are trading at ₹341.00 each on the NSE. The shares have increased by 6% today, peaking at ₹355.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
Published on: Dec 9, 2024, 3:26 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
